secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2025-07-02T23:59:59+00:00
Accession:  0001104659-25-065386
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent BioPharma prices $75M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Raised ~$75M gross; priced 2,482,692 shares at $19.50 and 1,363,469 pre-funded warrants at $19.4999.
- Underwriters have 30-day option to purchase up to 576,923 additional shares on same terms.
- Proceeds to fund firmonertinib and other pipeline programs, plus working capital.
- Expected close July 3, 2025; joint bookrunners: Goldman Sachs, Citigroup, Guggenheim Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465925065386/0001104659-25-065386-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465925065386/tm2519401d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-065386

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer